Changes of T cell subsets across treatments associated with prognosis in newly diagnosed follicular lymphoma
Abstract Follicular lymphoma (FL) is an immune-responsive tumor with spontaneous remission. T cells play a pivotal role in the anti-lymphoma immune response. However, the dynamics of T cells during treatment, their impact on FL clinical outcomes, and the risk factors contributing to T-cell cytopenia...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-11-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-79173-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846165349382225920 |
|---|---|
| author | Qiuhui Jiang Feng Lin Zhifeng Li Hongpeng Duan Chong Jiang Xingxing Yu Caiyan Wang Li Zhang Xiuhua Sun Jie Zha Long Liu Zhijuan Lin Bing Xu |
| author_facet | Qiuhui Jiang Feng Lin Zhifeng Li Hongpeng Duan Chong Jiang Xingxing Yu Caiyan Wang Li Zhang Xiuhua Sun Jie Zha Long Liu Zhijuan Lin Bing Xu |
| author_sort | Qiuhui Jiang |
| collection | DOAJ |
| description | Abstract Follicular lymphoma (FL) is an immune-responsive tumor with spontaneous remission. T cells play a pivotal role in the anti-lymphoma immune response. However, the dynamics of T cells during treatment, their impact on FL clinical outcomes, and the risk factors contributing to T-cell cytopenia remain largely unexplored. T-cell and their subsets in the peripheral blood of FL patients at diagnosis, during 2–4 cycles and after 6 cycles of treatment, as well as healthy individuals were detected by flow-cytometry. The predictive effects of T cells for early progression and risks for T-cell cytopenia were analyzed. FL patients exhibited a significant decrease in CD3+, CD4+, and CD8 + T cells compared to healthy individuals, with aging intensifying the decline of CD3+, and CD4 + T cells. Notably, a reduction in CD4 + T cells, predominantly contributing to treatment-related T-cell reduction, was only observed in patients undergoing Bendamustine-based regimens. Moreover, a significantly decreased CD4 + and CD8 + T-cell at diagnosis rather than after induction therapy was observed in patients with treatment failure. Furthermore, lower CD4 + T-cell (< 260/uL) at baseline was independently correlated to early progression within 24 months. Finally, disease stage and albumin were the independent predictive factors for the decline of CD4 + T cells in FL patients. Overall, FL patients demonstrated compromised T-cell immunity, with a lower CD4 + T cell count at diagnosis correlating with treatment response and early progression. Therefore, monitoring CD4 + T cells at diagnosis might reflect immune status and aid in stratifying FL patients. |
| format | Article |
| id | doaj-art-ae5af0df550a4f47bc1e8799bfd87d26 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-ae5af0df550a4f47bc1e8799bfd87d262024-11-17T12:23:50ZengNature PortfolioScientific Reports2045-23222024-11-0114111010.1038/s41598-024-79173-wChanges of T cell subsets across treatments associated with prognosis in newly diagnosed follicular lymphomaQiuhui Jiang0Feng Lin1Zhifeng Li2Hongpeng Duan3Chong Jiang4Xingxing Yu5Caiyan Wang6Li Zhang7Xiuhua Sun8Jie Zha9Long Liu10Zhijuan Lin11Bing Xu12Department of Hematology, Institute of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen UniversityDepartment of Hematology, Institute of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen UniversityDepartment of Hematology, Institute of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen UniversityDepartment of Hematology, Institute of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen UniversityDepartment of Nuclear Medicine, West China Hospital, Sichuan UniversityDepartment of Hematology, Institute of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen UniversityDepartment of Hematology, Institute of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen UniversityDepartment of Hematology, Institute of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen UniversityDepartment of Hematology, The Second Affiliated Hospital of Dalian Medical UniversityDepartment of Hematology, Institute of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen UniversityDepartment of Hematology, Institute of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen UniversityDepartment of Hematology, Institute of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen UniversityDepartment of Hematology, Institute of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen UniversityAbstract Follicular lymphoma (FL) is an immune-responsive tumor with spontaneous remission. T cells play a pivotal role in the anti-lymphoma immune response. However, the dynamics of T cells during treatment, their impact on FL clinical outcomes, and the risk factors contributing to T-cell cytopenia remain largely unexplored. T-cell and their subsets in the peripheral blood of FL patients at diagnosis, during 2–4 cycles and after 6 cycles of treatment, as well as healthy individuals were detected by flow-cytometry. The predictive effects of T cells for early progression and risks for T-cell cytopenia were analyzed. FL patients exhibited a significant decrease in CD3+, CD4+, and CD8 + T cells compared to healthy individuals, with aging intensifying the decline of CD3+, and CD4 + T cells. Notably, a reduction in CD4 + T cells, predominantly contributing to treatment-related T-cell reduction, was only observed in patients undergoing Bendamustine-based regimens. Moreover, a significantly decreased CD4 + and CD8 + T-cell at diagnosis rather than after induction therapy was observed in patients with treatment failure. Furthermore, lower CD4 + T-cell (< 260/uL) at baseline was independently correlated to early progression within 24 months. Finally, disease stage and albumin were the independent predictive factors for the decline of CD4 + T cells in FL patients. Overall, FL patients demonstrated compromised T-cell immunity, with a lower CD4 + T cell count at diagnosis correlating with treatment response and early progression. Therefore, monitoring CD4 + T cells at diagnosis might reflect immune status and aid in stratifying FL patients.https://doi.org/10.1038/s41598-024-79173-wFollicular lymphomaT cell subsetsLymphocyteOutcomes |
| spellingShingle | Qiuhui Jiang Feng Lin Zhifeng Li Hongpeng Duan Chong Jiang Xingxing Yu Caiyan Wang Li Zhang Xiuhua Sun Jie Zha Long Liu Zhijuan Lin Bing Xu Changes of T cell subsets across treatments associated with prognosis in newly diagnosed follicular lymphoma Scientific Reports Follicular lymphoma T cell subsets Lymphocyte Outcomes |
| title | Changes of T cell subsets across treatments associated with prognosis in newly diagnosed follicular lymphoma |
| title_full | Changes of T cell subsets across treatments associated with prognosis in newly diagnosed follicular lymphoma |
| title_fullStr | Changes of T cell subsets across treatments associated with prognosis in newly diagnosed follicular lymphoma |
| title_full_unstemmed | Changes of T cell subsets across treatments associated with prognosis in newly diagnosed follicular lymphoma |
| title_short | Changes of T cell subsets across treatments associated with prognosis in newly diagnosed follicular lymphoma |
| title_sort | changes of t cell subsets across treatments associated with prognosis in newly diagnosed follicular lymphoma |
| topic | Follicular lymphoma T cell subsets Lymphocyte Outcomes |
| url | https://doi.org/10.1038/s41598-024-79173-w |
| work_keys_str_mv | AT qiuhuijiang changesoftcellsubsetsacrosstreatmentsassociatedwithprognosisinnewlydiagnosedfollicularlymphoma AT fenglin changesoftcellsubsetsacrosstreatmentsassociatedwithprognosisinnewlydiagnosedfollicularlymphoma AT zhifengli changesoftcellsubsetsacrosstreatmentsassociatedwithprognosisinnewlydiagnosedfollicularlymphoma AT hongpengduan changesoftcellsubsetsacrosstreatmentsassociatedwithprognosisinnewlydiagnosedfollicularlymphoma AT chongjiang changesoftcellsubsetsacrosstreatmentsassociatedwithprognosisinnewlydiagnosedfollicularlymphoma AT xingxingyu changesoftcellsubsetsacrosstreatmentsassociatedwithprognosisinnewlydiagnosedfollicularlymphoma AT caiyanwang changesoftcellsubsetsacrosstreatmentsassociatedwithprognosisinnewlydiagnosedfollicularlymphoma AT lizhang changesoftcellsubsetsacrosstreatmentsassociatedwithprognosisinnewlydiagnosedfollicularlymphoma AT xiuhuasun changesoftcellsubsetsacrosstreatmentsassociatedwithprognosisinnewlydiagnosedfollicularlymphoma AT jiezha changesoftcellsubsetsacrosstreatmentsassociatedwithprognosisinnewlydiagnosedfollicularlymphoma AT longliu changesoftcellsubsetsacrosstreatmentsassociatedwithprognosisinnewlydiagnosedfollicularlymphoma AT zhijuanlin changesoftcellsubsetsacrosstreatmentsassociatedwithprognosisinnewlydiagnosedfollicularlymphoma AT bingxu changesoftcellsubsetsacrosstreatmentsassociatedwithprognosisinnewlydiagnosedfollicularlymphoma |